Bravecto vs Nexgard vs Simparica Comparison

Of course. This is a frequent and important clinical question. Let's break down the isoxazoline class from a pharmacologic and clinical perspective.

At their core, all isoxazolines share the same mechanism of action: they are non-competitive antagonists of GABA- and glutamate-gated chloride channels in invertebrate nervous systems. This leads to hyperexcitation and death of the parasite. The key differences between products lie in their pharmacokinetics, which dictates dosing interval, and subtle variations in their approved spectrum.

Here is a summary of the key clinical differentiators:

| Feature | Bravecto (fluralaner) | Nexgard (afoxolaner) | Simparica / Simparica Trio (sarolaner) |
| :--- | :--- | :--- | :--- |
| Dosing Interval | 12 weeks (8 weeks for A. americanum) | Monthly | Monthly |
| Speed of Kill (Fleas) | Starts killing in 2h; >95% efficacy by 8-12h | >99% efficacy by 8h | Starts killing in 3h; >99% efficacy by 8h |
| Speed of Kill (Ticks) | >90% efficacy by 12h for I. scapularis | >90% efficacy by 24-48h | >96% efficacy by 8h for I. scapularis |
| Tick Spectrum | Ixodes scapularis, Dermacentor variabilis, Rhipicephalus sanguineus, Amblyomma americanum | I. scapularis, D. variabilis, R. sanguineus, A. americanum | I. scapularis, D. variabilis, R. sanguineus, A. americanum, Amblyomma maculatum (Gulf Coast Tick) |
| Minimum Age | 6 months | 8 weeks | 6 months (Simparica) / 8 weeks (Trio) |
| Combination | No (topical version for cats adds moxidectin) | No | Simparica Trio: Adds moxidectin (HW) and pyrantel (round/hookworms) |

Key Safety Considerations

Neurologic Adverse Events (FDA Warning): This is a class-wide effect. The warning applies to all isoxazolines. The incidence of seizures, ataxia, and tremors is very low (in the "very rare" post-marketing category, <1 event per 10,000 doses). However, the risk is not zero. For patients with a pre-existing history of seizures, this requires a careful risk-benefit discussion with the owner. While you can still use them, it's prudent to document this conversation and consider alternatives if the owner is concerned or the seizures are poorly controlled.

MDR1/ABCB1-Mutant Breeds: Isoxazolines are substrates for P-glycoprotein (P-gp), the protein product of the ABCB1 gene. This is the mechanism by which the drug is normally effluxed from the central nervous system. In homozygous mutant dogs, this pump is non-functional. However, multiple safety studies have shown that all approved isoxazolines are safe in MDR1-mutant dogs at their labeled doses, and in some cases up to 5x the labeled dose. The risk of neurologic toxicity at the approved dose is considered very low, as the therapeutic margin is wide enough to account for the lack of P-gp efflux.

Clinical Decision-Making Framework

Choosing the right product depends on the patient and owner profile:

* For Owner Compliance: Bravecto's 12-week duration is a significant advantage for owners who struggle with monthly compliance. This is arguably its strongest feature. Remember to advise them of the 8-week duration for Lone Star ticks if they live in an endemic area.
* For Severe Flea Allergy Dermatitis (FAD): Simparica has the fastest onset of flea kill based on label data. For a profoundly allergic animal, killing fleas as rapidly as possible is the priority, making it an excellent choice.
For Broadest Tick Coverage: If the patient is in the Gulf Coast region where Amblyomma maculatum* is a concern, Simparica/Simparica Trio holds the specific label claim for that species.
* For the Youngest Puppies: Nexgard and Simparica Trio are approved for use starting at 8 weeks of age, whereas Bravecto and standalone Simparica require the patient to be 6 months old.
* For Simplicity/Combination Therapy: Simparica Trio offers a convenient all-in-one oral product for fleas, ticks, heartworm, and common intestinal parasites. This is ideal for owners who want to minimize the number of monthly medications.

Ultimately, all are highly effective and safe products. The choice comes down to prioritizing owner compliance, specific parasite risk, patient age, and the value of a combination product. The seizure risk is a class effect and a crucial counseling point for any patient, but especially for those with a known neurologic history.